Serum 5-hydroxytryptamine levels as biomarkers for motor dysfunction and depression in Parkinson’s disease patients

doi:10.5498/wjp.v16.i4.114462

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

(48)

(50)

(0)

(18)

(1)

(592)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Psychiatry. Apr 19, 2026; 16(4): 114462
Published online Apr 19, 2026. doi: 10.5498/wjp.v16.i4.114462

Table 4 Multivariate analysis and risk factors

Endpoint	Variable	OR	95%CI	P value	AUC 95%CI
Dyskinesia	Age at onset	0.921	0.867-0.979	0.009	0.867 (0.785-0.949)
	Duration of dopaminergic treatment	1.298	1.112-1.515	0.001
	Maximum daily levodopa dose	1.003	1.001-1.005	0.008
	Serum 5-HT level	0.984	0.975-0.993	0.001
Depression	H-Y staging	2.156	1.234-3.767	0.007	0.823 (0.731-0.915)
	UPDRS I	1.387	1.178-1.632	0.001
	Disease duration	1.142	1.012-1.289	0.031
	Serum 5-HT level	0.981	0.971-0.991	0.001

5-HT: 5-hydroxytryptamine; H-Y: Hoehn-Yahr; UPDRS: Unified Parkinson’s Disease Rating Scale; OR: Odds ratio; CI: Confidence interval; AUC: Area under the curve.

Full Size Table

Citation: Chen YS, Yang SY, Lu KY, Li M, Liu T, Zhu SG, Lu HL, Hu K. Serum 5-hydroxytryptamine levels as biomarkers for motor dysfunction and depression in Parkinson’s disease patients. World J Psychiatry 2026; 16(4): 114462
URL: https://www.wjgnet.com/2220-3206/full/v16/i4/114462.htm
DOI: https://dx.doi.org/10.5498/wjp.v16.i4.114462

Chen YS, Yang SY, Lu KY, Li M, Liu T, Zhu SG, Lu HL, Hu K. Serum 5-hydroxytryptamine levels as biomarkers for motor dysfunction and depression in Parkinson’s disease patients. World J Psychiatry 2026; 16(4): 114462 [DOI: 10.5498/wjp.v16.i4.114462]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.